Novo Nordisk adds Mars CEO as board observer
Source: SeekingAlpha
2026-03-26 11:57:16 ET
More on Novo Nordisk A/S
- Novo Nordisk: The Illusion Of Cheap
- Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)
- Novo Nordisk: Buying The Dip Before Volume Dominance
- Novo’s China obesity drug posts positive mid-stage trial results
- Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
Read the full article on Seeking Alpha
For further details see:
Novo Nordisk adds Mars CEO as board observer
Novo Nordisk A/S
NASDAQ: NVO
NVO Trading
-1.59% G/L:
$43.335 Last:
5,766,679 Volume:
$44.05 Open:
NVO Latest News
June 06, 2026 09:35:00 am
Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now?
June 04, 2026 09:47:47 am
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
NVO Stock Data
$220,548,675,000
4,194,421,000
N/A
749
N/A
Biotechnology & Life Sciences
Healthcare
DK
Bagsvaerd
